É V Nesterenko

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant(More)
  • 1